Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Enlivex Therapeutics Ltd - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ENLV
Nasdaq
8731
https://www.enlivex.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Enlivex Therapeutics Ltd
Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events
- Apr 29th, 2024 12:00 pm
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
- Apr 22nd, 2024 12:00 pm
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
- Apr 16th, 2024 11:50 am
Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why
- Apr 15th, 2024 5:01 pm
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
- Apr 11th, 2024 6:58 pm
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
- Apr 11th, 2024 12:05 pm
Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
- Mar 22nd, 2024 2:50 pm
Enlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis
- Feb 26th, 2024 1:30 pm
Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals
- Feb 21st, 2024 1:30 pm
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method
- Feb 7th, 2024 1:00 pm
Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis
- Jan 17th, 2024 1:00 pm
Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis
- Dec 20th, 2023 1:00 pm
Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?
- Dec 12th, 2023 10:49 am
MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer
- Nov 21st, 2023 12:00 pm
Enlivex to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Sep 7th, 2023 12:00 pm
Enlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating Allocetra in Patients with COVID-19
- Aug 2nd, 2023 12:00 pm
Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis
- Jul 31st, 2023 12:00 pm
Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update
- Jun 26th, 2023 12:00 pm
Enlivex to Present at the 2023 Jefferies Healthcare Conference
- Jun 6th, 2023 12:00 pm
Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy
- May 31st, 2023 12:04 pm
Scroll